Recent inspections by the U.S. Food & Drug Administration at Novo Nordisk’s largest U.S. semaglutide plant discovered “objectionable” items. During routine inspections this year, FDA officials found bacterial contamination on three separate occasions. The agency issued a Form 483 to Novo following the inspections, listing numerous…
Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.
Drugwatch's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.
